JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
According to a report by French news outlet La Lettre on 12 January Eli Lilly is said to be working on a potential €15bn ($17.5bn) deal for Abivax, a company developing anti-inflammatory drugs. Eli Lilly declined to comment on business development activity, and Abivax did not immediately respond to Pharmaceutical Technology 's request regarding the potential deal. Share price in Paris-listed Abivax opened 17.5% up at €120 at market open on 12 January, compared to market close of €99 on 9 January. The biotech, which is also listed on the Nasdaq Global Market, has a market cap of €8.4bn. Abivax's lead asset is obefazimod, an orally administered small molecule that increases the anti-inflammatory microRNA, miR-124, in immune cells. The therapy has demonstrated positive Phase III results as a monotherapy in patients with moderate to severely active ulcerative colitis (UC). Obefazimod is also in Phase II clinical development (NCT06456593) for Crohn's disease. In a corporate update
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines (NASDAQ:RVMD) was given a new $143.00 price target on by analysts at Mizuho.MarketBeat
- JPM 26: Day 1 – drug prices and policy changes drive the agenda [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines declines to comment on M&A speculation at conference [Seeking Alpha]Seeking Alpha
- AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines: Take The Win And Sell Following Large Move Sparked By Buyout Rumors [Seeking Alpha]Seeking Alpha
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/7/26 - Form 144
- RVMD's page on the SEC website